Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis

The mechanism by which leptin reverses diabetic ketoacidosis (DKA) is unknown. We examined the acute insulin-independent effects of leptin replacement therapy in a streptozotocin-induced rat model of DKA. Leptin infusion reduced rates of lipolysis, hepatic glucose production (HGP), and hepatic ketogenesis by 50% within 6 hours and were independent of any changes in plasma glucagon concentrations; these effects were abrogated by coinfusion of corticosterone. Treating leptin- and corticosterone-infused rats with an adipose triglyceride lipase inhibitor blocked corticosterone-induced increases in plasma glucose concentrations and rates of HGP and ketogenesis. Similarly, adrenalectomized type 1 diabetic (T1D) rats exhibited decreased rates of lipolysis, HGP, and ketogenesis; these effects were reversed by corticosterone infusion. Leptin-induced decreases in lipolysis, HGP, and ketogenesis in DKA were also nullified by relatively small increases (15 to 70 pM) in plasma insulin concentrations. In contrast, the chronic glucose-lowering effect of leptin in a STZ-induced mouse model of poorly controlled T1D was associated with decreased food intake, reduced plasma glucagon and corticosterone concentrations, and decreased ectopic lipid (triacylglycerol/diacylglycerol) content in liver and muscle. Collectively, these studies demonstrate marked differences in the acute insulin-independent effects by which leptin reverses fasting hyperglycemia and ketoacidosis in a rodent model of DKA versus the chronic pleotropic effects by which leptin reverses hyperglycemia in a non-DKA rodent model of T1D.

[1]  Michael J. Marcel,et al.  Insulin receptor Thr 1160 phosphorylation mediates lipid-induced hepatic insulin resistance , 2018 .

[2]  Michael J. Marcel,et al.  Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. , 2016, The Journal of clinical investigation.

[3]  Jeffrey T. Chang,et al.  Euglycemia Restoration by Central Leptin in Type 1 Diabetes Requires STAT3 Signaling but Not Fast-Acting Neurotransmitter Release , 2016, Diabetes.

[4]  G. Shulman,et al.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. , 2016, The Journal of clinical investigation.

[5]  M. Schwartz,et al.  Evidence against hypothalamic-pituitary-adrenal axis suppression in the antidiabetic action of leptin. , 2015, The Journal of clinical investigation.

[6]  J. Brüning,et al.  Metabolism: Light on leptin link to lipolysis , 2015, Nature.

[7]  G. Shulman,et al.  FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis , 2015, Nature Communications.

[8]  K. Petersen,et al.  Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes , 2015, Cell.

[9]  J. Ayala,et al.  Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes , 2014, Molecular metabolism.

[10]  G. Shulman.  Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. , 2014, The New England journal of medicine.

[11]  G. Shulman,et al.  Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis , 2014, Nature Medicine.

[12]  R. Zechner,et al.  Development of small molecule inhibitors targeting adipose triglyceride lipase , 2013, Nature chemical biology.

[13]  Vishal R. Patel,et al.  Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin. , 2013, Cell metabolism.

[14]  G. Taborsky,et al.  Leptin action in the ventromedial hypothalamic nucleus is sufficient, but not necessary, to normalize diabetic hyperglycemia. , 2013, Endocrinology.

[15]  D. W. Foster.  Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. , 2012, The Journal of clinical investigation.

[16]  F. Haj,et al.  Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats , 2011, Proceedings of the National Academy of Sciences.

[17]  Scott D Covey,et al.  Leptin Therapy Reverses Hyperglycemia in Mice With Streptozotocin-Induced Diabetes, Independent of Hepatic Leptin Signaling , 2011, Diabetes.

[18]  R. Coppari,et al.  Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice , 2010, Proceedings of the National Academy of Sciences.

[19]  O. Ilkayeva,et al.  Leptin therapy in insulin-deficient type I diabetes , 2010, Proceedings of the National Academy of Sciences.

[20]  Byung-Hyun Park,et al.  Making insulin-deficient type 1 diabetic rodents thrive without insulin , 2008, Proceedings of the National Academy of Sciences.

[21]  D. Kleiner,et al.  Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  G. Shulman,et al.  Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.

[23]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[24]  Chia-yu Lin,et al.  Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. , 2002, American journal of physiology. Endocrinology and metabolism.

[25]  H. Yoshimatsu,et al.  Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin‐induced diabetic rats , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  N. Chinookoswong,et al.  Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. , 1999, Diabetes.

[27]  J. Katz.  On the determination of turnover in vivo with tracers. , 1992, The American journal of physiology.

[28]  R. DeFronzo,et al.  Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. , 1987, The Journal of clinical investigation.

[29]  R. Wolfe,et al.  Sample site selection for tracer studies applying a unidirectional circulatory approach. , 1987, The American journal of physiology.

[30]  R. DeFronzo,et al.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.

[31]  A. Dunn,et al.  The determination of lactate turnover in vivo with 3H- and 14C-labelled lactate. The significance of sites of tracer administration and sampling. , 1981, The Biochemical journal.

[32]  J. McGarry,et al.  A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. , 1977, The Journal of clinical investigation.

[33]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.